SKAN Group (SKAN) H2 2025 earnings summary

Executive summary

• Order intake increased 3.1% year-over-year to CHF 370.6 million, with strong demand in Europe and a cautious U.S. market; order backlog rose 8.7% to CHF 346.1 million, supporting future visibility.

• Net sales declined 7.7% to CHF 333.3 million due to above-average project postponements, mainly vaccine lines deprioritized by customers, shifting revenue recognition to 2026 and 2027.

• EBITDA dropped 32.3% to CHF 38.6 million (margin 11.6%), but profitability rebounded in H2 with a 19% margin, driven by catch-up sales and improved cost structure.

• Two strategic acquisitions (Metronik and ABC Transfer) expanded the high-margin Services and Consumables segment, supporting recurring revenue growth.

• Net profit reached CHF 17.6 million; proposed dividend of CHF 0.22 per share (30% payout ratio).

Financial highlights

• Order backlog rose to CHF 346.1 million (+8.7% y-o-y), providing strong visibility for future periods.

• Net sales in H2 increased 48% over H1, reflecting recovery from project delays.

• Operating cash flow surged 37.3% to CHF 64.1 million, supported by advance payments and disciplined working capital.

• Net debt at year-end was CHF 37.4 million (net debt/EBITDA ratio 0.97), reflecting acquisition financing and low leverage.

• Equity ratio declined to 26.5% due to goodwill from acquisitions, not structural weakness.

Outlook and guidance

• 2026 sales growth expected in the upper teens percentage; EBITDA margin forecast at 13%-15%.

• Midterm outlook: mid to upper teens sales growth, gradual EBITDA margin increase to upper teens.

• Management expects a softer H1 2026 due to project timing, with stronger H2 performance anticipated.

• Guidance assumes no major tariff escalations, limited impact from geopolitical conflicts, and no significant currency effects.

• Services and Consumables, including Pre-Approved Services, are key growth and margin drivers.